Clinical Trials Directory

Trials / Unknown

UnknownNCT05623904

Carotid Revascularization Versus Best Medical Treatment for Asymptomatic Carotid Stenosis

Carotid Revascularization Versus Best Medical Treatment for Asymptomatic Carotid Stenosis: a Multicenter, Open, Randomized Controlled Trial in Chinese Population

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
1,056 (estimated)
Sponsor
Xuanwu Hospital, Beijing · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population.

Detailed description

This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population. The study will be conducted at 11 centers and is expected to enroll 1056 patients.

Conditions

Interventions

TypeNameDescription
PROCEDURECarotid RevascularizationCarotid Artery Stenting/Carotid Endarterectomy
DRUGMedical TreatmentAspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up. In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.

Timeline

Start date
2022-10-14
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2022-11-21
Last updated
2023-01-31

Locations

11 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05623904. Inclusion in this directory is not an endorsement.